Marker Therapeutics (MRKR) Share-based Compensation (2010 - 2026)
Marker Therapeutics (MRKR) reported Share-based Compensation of $178422.0 for Q1 2026, down 52.94% year-over-year from $379144.0 in Q1 2025, and up 60.55% quarter-over-quarter from $111131.0 in Q4 2025.
Marker Therapeutics (MRKR) Share-based Compensation (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 17 years of Share-based Compensation data on file, last reported at $178422.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $178422.0, down 52.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $336553.0 (down 38.33% YoY), and the FY2025 annual result was $537540.0, up 118.63% from the prior year.
- Share-based Compensation grew to $178422.0 in Q1 2026 per MRKR's latest filing, from $111131.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.6 million in Q1 2022 and troughed at $14000.0 in Q2 2025.
- A 5-year average of $464193.4 and a median of $175000.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 89.6% in 2024, then jumped 379.93% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $717000.0 in 2022, then slumped by 80.0% to $143370.0 in 2023, then plunged by 64.75% to $50544.0 in 2024, then jumped by 119.87% to $111131.0 in 2025, then jumped by 60.55% to $178422.0 in 2026.
- Business Quant data shows MRKR's Share-based Compensation at $178422.0 in Q1 2026, $111131.0 in Q4 2025, and $33000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | 178,422.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178,422.00 |
| Mar 31, 2026 | 178,422.00 |
| Dec 31, 2025 | 111,131.00 |
| Dec 31, 2025 | 111,131.00 |
| Sep 30, 2025 | 33,000.00 |
| Sep 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 379,144.00 |
| Mar 31, 2025 | 379,144.00 |
| Dec 31, 2024 | 50,544.00 |
| Dec 31, 2024 | 50,544.00 |
| Sep 30, 2024 | 53,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 63,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 143,370.00 |
| Dec 31, 2023 | 143,370.00 |